tiprankstipranks
Trending News
More News >
Bristol-Myers Squibb (BMY)
NYSE:BMY
Advertisement

Bristol-Myers Squibb (BMY) AI Stock Analysis

Compare
11,643 Followers

Top Page

BMY

Bristol-Myers Squibb

(NYSE:BMY)

Rating:68Neutral
Price Target:
$52.00
▲(10.31% Upside)
Bristol-Myers Squibb's overall stock score reflects strong financial performance and strategic growth initiatives, as highlighted in the earnings call. The company's robust cash flow and attractive dividend yield further support its valuation. However, high leverage and challenges in legacy portfolios present risks that need to be managed for sustained growth.
Positive Factors
Financial Performance
Guidance for FY25 revenue was raised by $700 million, indicating strong future performance expectations.
Operational Efficiency
Bristol is making solid progress with a $1 billion reduction in OPEX this year and clear reallocation in the pipeline.
Negative Factors
Product Launches
The price target was lowered to $58 due to a slower Cobenfy launch and more uncertainty on future expansions.
Quality of Earnings
Concerns remain around the quality of the earnings beat, particularly the reliance on lower quality items such as legacy products, FX, and stocking.
Revenue Expectations
Cobenfy scripts are expected to miss Visible Alpha consensus estimates for 3Q25 revenue.

Bristol-Myers Squibb (BMY) vs. SPDR S&P 500 ETF (SPY)

Bristol-Myers Squibb Business Overview & Revenue Model

Company DescriptionBristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
How the Company Makes MoneyBristol-Myers Squibb generates revenue primarily through the sale of prescription pharmaceutical products. The company's key revenue streams include sales of its oncology drugs, such as Opdivo and Revlimid, alongside its cardiovascular product, Eliquis. These drugs are often prescribed for long-term treatment, resulting in recurring revenue. Additionally, BMY benefits from partnerships and collaborations with other pharmaceutical companies and research institutions, which can provide additional revenue through shared development costs and royalties. The company also engages in licensing agreements that contribute to its earnings. Overall, BMY's diverse product portfolio, combined with strategic collaborations and a focus on high-demand therapeutic areas, underpins its financial performance.

Bristol-Myers Squibb Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes revenue from different business segments, highlighting which areas drive growth and profitability, and indicating how well the company diversifies its income streams.
Chart InsightsBristol-Myers Squibb's 'Other' segment revenue surged in late 2024, possibly reflecting strategic shifts or new product launches, aligning with the earnings call's emphasis on growth portfolio performance. The 'Product' segment shows resilience with a recent uptick, while 'Alliance' revenue is declining, consistent with challenges in legacy portfolios. The earnings call highlights robust demand for key brands and raised revenue guidance, suggesting confidence in sustained growth despite some unmet expectations in trials.
Data provided by:Main Street Data

Bristol-Myers Squibb Earnings Call Summary

Earnings Call Date:Aug 01, 2025
(Q2-2025)
|
% Change Since: 8.84%|
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong performance in the growth portfolio and successful strategic initiatives, with increased revenue and earnings guidance. Despite challenges in the legacy portfolio and some study outcomes not meeting expectations, the company is well-positioned for long-term growth with a robust pipeline and strategic partnerships.
Q2-2025 Updates
Positive Updates
Strong Growth Portfolio Performance
The growth portfolio delivered a 17% year-over-year increase, driven by demand across key brands like Opdivo, Breyanzi, Reblozyl, and Camzyos. Global sales of growth portfolio increased significantly, contributing to a total company revenue of approximately $12.3 billion.
Regulatory Approvals and Strategic Partnerships
Secured approval for Opdivo in neoadjuvant lung cancer and for Qvantig across multiple solid tumor indications in Europe. Announced partnerships with BioNTech to co-develop a PD-L1 VEGF bispecific and Philochem for rights to OncoACP3, enhancing the company's position in oncology and radiopharmaceuticals.
Increased Revenue and Earnings Guidance
Raised full year reported revenue guidance by $700 million at the midpoint to a range of $46.5 billion to $47.5 billion. Also improved non-GAAP EPS guidance after considering strong performance year-to-date.
Successful New Launches
Cobenfy and Qvantig launched successfully, with Cobenfy delivering strong performance and positive physician feedback. Qvantig saw strong uptake in the U.S., optimizing treatment efficiency.
Financial Position and Capital Allocation
Strong financial position with $13.9 billion in cash and equivalents. Generated $3.9 billion in operating cash flow in Q2, with priorities on growth portfolio investments and strategic capital allocation.
Negative Updates
Challenges in Legacy Portfolio
Legacy portfolio expected to decline by 15% to 17% for the year, with specific challenges in products like Abraxane, Sprycel, and Pomalyst.
Unfavorable Study Outcomes
Some studies did not meet expected outcomes, though their impact on long-term growth is limited. The company is reviewing near-term studies to ensure successful delivery.
Regulatory and Market Pressures
Facing macro and industry pressures, including navigating regulatory changes and potential competition from new market entrants like Aficamten.
Company Guidance
During the Bristol-Myers Squibb second quarter 2025 earnings call, the company reported strong financial performance, with total revenues reaching approximately $12.3 billion, driven by a 17% year-over-year sales increase in their growth portfolio. The oncology portfolio, including Opdivo, contributed significantly with $2.6 billion in sales, while the hematology portfolio, highlighted by Reblozyl and Breyanzi, also showed robust growth. The cardiovascular segment, led by Camzyos, marked a notable 86% increase in sales. The company raised its full-year revenue guidance to a range of $46.5 billion to $47.5 billion and adjusted its non-GAAP EPS guidance to $6.35 to $6.65. Bristol-Myers Squibb announced strategic partnerships, including with BioNTech for a PD-L1 VEGF bispecific, and continued to invest in its pipeline with several Phase III trials and life cycle management opportunities on the horizon. The company emphasized its focus on long-term sustainable growth and strategic capital deployment, including a plan to pay down $10 billion of debt by the first half of 2026.

Bristol-Myers Squibb Financial Statement Overview

Summary
Bristol-Myers Squibb demonstrates resilient financial performance with strengths in cash flow generation and gross profitability. However, net income variability and increased leverage pose potential risks. Continued focus on stabilizing earnings and managing liabilities will be crucial for sustained financial health.
Income Statement
72
Positive
The income statement reveals a stable performance with gross profit margins consistently strong around 70%. However, the net profit margin has fluctuated significantly, with a notable loss in 2024. Revenue growth has been stable, with a slight decline in recent periods. The EBIT and EBITDA margins are solid for the TTM, reflecting efficient cost management despite earlier fluctuations.
Balance Sheet
65
Positive
The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. The equity ratio has decreased over time, suggesting an increase in liabilities relative to assets. Return on equity has varied, impacted by fluctuating net income, with a recent improvement in profitability contributing positively.
Cash Flow
75
Positive
Cash flow analysis is favorable, with strong and improving free cash flow, highlighting efficient cash generation. The operating cash flow to net income ratio indicates robust cash conversion efficiency, although historical net income volatility presents some risk. Free cash flow growth is positive, supporting a strong cash position.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue47.70B48.30B45.01B46.16B46.38B42.52B
Gross Profit29.45B27.43B25.36B26.49B26.76B21.70B
EBITDA15.09B3.17B19.37B19.22B20.12B4.93B
Net Income5.05B-8.95B8.03B6.33B6.99B-8.99B
Balance Sheet
Total Assets94.68B92.60B95.16B96.82B109.31B118.48B
Cash, Cash Equivalents and Short-Term Investments13.60B10.86B12.28B9.25B17.22B16.45B
Total Debt50.93B51.20B41.46B40.72B45.60B51.67B
Total Liabilities77.19B76.22B65.67B65.70B73.31B80.60B
Stockholders Equity17.43B16.34B29.43B31.06B35.95B37.82B
Cash Flow
Free Cash Flow14.58B13.94B12.65B11.95B15.23B13.30B
Operating Cash Flow15.90B15.19B13.86B13.07B16.21B14.05B
Investing Cash Flow-1.39B-21.35B-2.29B-1.06B-538.00M-10.86B
Financing Cash Flow-8.32B5.13B-9.42B-16.96B-16.22B-1.15B

Bristol-Myers Squibb Technical Analysis

Technical Analysis Sentiment
Negative
Last Price47.14
Price Trends
50DMA
46.95
Positive
100DMA
47.79
Negative
200DMA
52.10
Negative
Market Momentum
MACD
0.32
Negative
RSI
49.60
Neutral
STOCH
49.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMY, the sentiment is Negative. The current price of 47.14 is above the 20-day moving average (MA) of 46.63, above the 50-day MA of 46.95, and below the 200-day MA of 52.10, indicating a neutral trend. The MACD of 0.32 indicates Negative momentum. The RSI at 49.60 is Neutral, neither overbought nor oversold. The STOCH value of 49.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMY.

Bristol-Myers Squibb Risk Analysis

Bristol-Myers Squibb disclosed 23 risk factors in its most recent earnings report. Bristol-Myers Squibb reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Bristol-Myers Squibb Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$147.14B13.7612.16%6.80%14.72%
81
Outperform
$218.23B13.4735.44%3.75%2.00%20.01%
78
Outperform
$80.45B18.5023.04%4.15%3.46%-13.29%
68
Neutral
$97.54B19.3429.31%5.13%2.57%
68
Neutral
$142.41B22.8333.26%2.72%3.69%501.26%
67
Neutral
$158.13B24.0399.14%3.26%13.10%110.67%
51
Neutral
$7.78B-0.06-39.91%2.29%21.32%-1.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BMY
Bristol-Myers Squibb
47.14
1.18
2.57%
AMGN
Amgen
288.47
-27.88
-8.81%
GILD
Gilead Sciences
114.15
39.56
53.04%
GSK
GlaxoSmithKline
39.64
-2.61
-6.18%
MRK
Merck & Company
85.31
-27.39
-24.30%
PFE
Pfizer
25.14
-1.79
-6.65%

Bristol-Myers Squibb Corporate Events

Business Operations and StrategyFinancial Disclosures
Bristol-Myers Squibb Q2 2025 Financial Results Released
Positive
Jul 31, 2025

On July 31, 2025, Bristol Myers Squibb reported its financial results for the second quarter of 2025, highlighting a total revenue of $12.3 billion, a 1% increase from the previous year. The company’s Growth Portfolio revenues rose by 18%, driven by strong performances in its immuno-oncology products, while the Legacy Portfolio saw a decline due to generic competition and Medicare Part D impacts. The company raised its 2025 revenue guidance and emphasized its focus on advancing transformational medicines and pipeline opportunities to sustain long-term growth.

The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.

Executive/Board Changes
Bristol-Myers Squibb Appoints New Chief Medical Officer
Neutral
Jul 25, 2025

On July 25, 2025, Bristol Myers Squibb announced the departure of Dr. Samit Hirawat, the Chief Medical Officer and Head of Development, effective November 1, 2025. Dr. Hirawat will transition to an advisory role starting August 1, 2025, and will receive severance benefits and prorated incentives. Concurrently, Dr. Cristian Massacesi will join the company as the new Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. Dr. Massacesi brings extensive experience from his previous roles at AstraZeneca and Alexion, and his appointment is expected to bolster Bristol Myers Squibb’s efforts in advancing its product pipeline and achieving regulatory approvals.

The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 14, 2025